Compare NVAX & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVAX | AZTA |
|---|---|---|
| Founded | 1987 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 1996 | 1996 |
| Metric | NVAX | AZTA |
|---|---|---|
| Price | $10.09 | $20.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $11.33 | ★ $42.60 |
| AVG Volume (30 Days) | ★ 4.2M | 740.0K |
| Earning Date | 05-20-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 309.76 | 60.52 |
| EPS | ★ 2.58 | N/A |
| Revenue | ★ $1,123,479,000.00 | $593,821,000.00 |
| Revenue This Year | N/A | $6.25 |
| Revenue Next Year | N/A | $5.42 |
| P/E Ratio | $3.97 | ★ N/A |
| Revenue Growth | ★ 64.69 | N/A |
| 52 Week Low | $5.01 | $21.29 |
| 52 Week High | $11.85 | $41.73 |
| Indicator | NVAX | AZTA |
|---|---|---|
| Relative Strength Index (RSI) | 55.12 | 18.39 |
| Support Level | $7.81 | N/A |
| Resistance Level | $10.42 | $31.87 |
| Average True Range (ATR) | 0.73 | 1.07 |
| MACD | -0.02 | -0.21 |
| Stochastic Oscillator | 36.18 | 6.72 |
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.